Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3702 with Immunochemotherapy for B-cell Lymphoma
NCT06566586Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQB3702 in B cell lymphoma, diffuse large B-cell lymphoma (DLBCL), indolent B-cell lymphoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Nov 2024; status: recruiting.
02
Drugs
TQB3702
03
Conditions
B cell lymphomadiffuse large B-cell lymphoma (DLBCL)indolent B-cell lymphoma
Beyond the preview
Go deeper on NCT06566586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06566586.